Form 4: Insmed Inc. Executive Roger Adsett Reports Stock and Option Awards

Roger Adsett, Chief Operating Officer of Insmed Inc., reports the acquisition of restricted stock units and stock options.

Summary

• On May 15, 2025, Roger Adsett, the Chief Operating Officer of Insmed Inc., was granted 6,508 restricted stock units (RSUs) and 31,610 stock options.
• The RSUs vest 25% on the first day of the month following the first anniversary of the grant date, and then 25% annually thereafter.
• The stock options vest 25% on the initial vesting date and an additional 12.5% every six months thereafter until fully vested.
• Following these transactions, Adsett beneficially owns 143,183 shares of Insmed Inc. common stock and 31,610 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices, aligning management with shareholder interests.

Positives

• The grant of RSUs and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock options and RSU grants are common forms of executive compensation in the pharmaceutical industry, aligning management incentives with company performance and shareholder value.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice among publicly traded biotechnology companies like Insmed.
• Companies such as Vertex Pharmaceuticals and Amgen also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules and grant sizes are generally benchmarked against peer companies to ensure competitiveness and retention.

Stakeholder Impact

• The grant of equity-based compensation aims to align management's interests with those of shareholders, potentially driving long-term value creation.
• Employees may view the executive compensation positively, as it reflects the company's commitment to incentivizing its leadership.

Key Dates

Keywords

Insmed, Roger Adsett, RSU, Stock Options, Beneficial Ownership, Form 4, Executive Compensation